$9.19
-0.03-0.33%
At close: -
$9.68
0.495.33%
After Hours: Mar 31, 4:03 PM EDT
Comments
Loading...
Latest Astellas Pharma Stock News | OTC:ALPMY | Benzinga
Get the latest news on Astellas Pharma stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Astellas Pharma performance
Categories: All
Tuesday, March 18, 2025
Thursday, February 13, 2025
Tuesday, February 11, 2025
Monday, January 06, 2025
Friday, January 03, 2025
Tuesday, December 31, 2024
Wednesday, October 16, 2024
Wednesday, October 09, 2024
Thursday, September 19, 2024
Wednesday, August 28, 2024
Tuesday, August 27, 2024
Monday, August 05, 2024
Friday, July 26, 2024
Tuesday, May 21, 2024
Thursday, May 02, 2024
Wednesday, April 24, 2024
Monday, March 04, 2024
Wednesday, January 31, 2024
Friday, December 29, 2023
Thursday, December 28, 2023
Monday, December 18, 2023
Saturday, December 16, 2023
Monday, December 11, 2023
Friday, November 17, 2023
Sunday, October 22, 2023
Thursday, October 05, 2023
Friday, September 22, 2023
Wednesday, September 20, 2023
Wednesday, July 12, 2023
Friday, July 07, 2023
Thursday, July 06, 2023
Thursday, June 08, 2023
Monday, May 15, 2023
Monday, May 01, 2023
- Pfizer, Astellas' Xtandi Combo Therapy Cuts Risk Of Metastasis, Death In Prostate Cancer By 58%
- Stocks Rise As Investors Welcome JPMorgan's Purchase Of First Republic's Assets; Treasury Yields Rise As Banking Crisis Recedes
- First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
- Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'